The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial
Open accessAbstract
IMPORTANCE: Deutetrabenazine is a novel molecule containing deuterium, which attenuates CYP2D6 metabolism and increases active metabolite half-lives and may therefore lead to stable systemic exposure while preserving key pharmacological activity. OBJECTIVE: To evaluate efficacy and safety of deutetrabenazine treatment to control chorea associated with Huntington disease. DESIGN, SETTING, AND PARTICIPANTS: Ninety ambulatory adults diagnosed with manifest Huntington disease and a baseline total maximal chorea score of 8 or higher (range, 0-28; lower score indicates less chorea) were enrolled from August 2013 to August 2014 and randomized to receive deutetrabenazine (n = 45) or placebo (n = 45) in a double-blind fashion at 34 Huntington Study Group sites. INTERVENTIONS: Deutetrabenazine or placebo was titrated to optimal dose level over 8 weeks and maintained for 4 weeks, followed by a 1-week washout. MAIN OUTCOMES AND MEASURES: Primary end point was the total maximal chorea score change from baseline (the average of values from the screening and day-0 visits) to maintenance therapy (the average of values from the week 9 and 12 visits) obtained by in-person visits. This study was designed to detect a 2.7-unit treatment difference in scores. The secondary end points, assessed hierarchically, were the proportion of patients who achieved treatment success on the Patient Global Impression of Change (PGIC) and on the Clinical Global Impression of Change (CGIC), the change in 36-Item Short Form- physical functioning subscale score (SF-36), and the change in the Berg Balance Test. RESULTS: Ninety patients with Huntington disease (mean age, 53.7 years; 40 women [44.4%]) were enrolled. In the deutetrabenazine group, the mean total maximal chorea scores improved from 12.1 (95% CI, 11.2-12.9) to 7.7 (95% CI, 6.5-8.9), whereas in the placebo group, scores improved from 13.2 (95% CI, 12.2-14.3) to 11.3 (95% CI, 10.0-12.5); the mean between-group difference was -2.5 units (95% CI, -3.7 to -1.3) (P < .001). Treatment success, as measured by the PGIC, occurred in 23 patients (51%) in the deutetrabenazine group vs 9 (20%) in the placebo group (P = .002). As measured by the CGIC, treatment success occurred in 19 patients (42%) in the deutetrabenazine group vs 6 (13%) in the placebo group (P = .002). In the deutetrabenazine group, the mean SF-36 physical functioning subscale scores decreased from 47.5 (95% CI, 44.3-50.8) to 47.4 (44.3-50.5), whereas in the placebo group, scores decreased from 43.2 (95% CI, 40.2-46.3) to 39.9 (95% CI, 36.2-43.6), for a treatment benefit of 4.3 (95% CI, 0.4 to 8.3) (P = .03). There was no difference between groups (mean difference of 1.0 unit; 95% CI, -0.3 to 2.3; P = .14), for improvement in the Berg Balance Test, which improved by 2.2 units (95% CI, 1.3-3.1) in the deutetrabenazine group and by 1.3 units (95% CI, 0.4-2.2) in the placebo group. Adverse event rates were similar for deutetrabenazine and placebo, including depression, anxiety, and akathisia. CONCLUSIONS AND RELEVANCE: Among patients with chorea associated with Huntington disease, the use of deutetrabenazine compared with placebo resulted in improved motor signs at 12 weeks. Further research is needed to assess the clinical importance of the effect size and to determine longer-term efficacy and safety. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01795859.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb09716.x · Cited by 47,139
(1992) · PubMed · Cited by 33,716
The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment
Nasreddine, Z. S., Phillips, N. A., Bédirian, V., Charbonneau, S., Whitehead, V., Collin, I., Cummings, J. L., & Chertkow, H. (2005) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2005.53221.x · Cited by 25,553
A New Method for Measuring Daytime Sleepiness: The Epworth Sleepiness Scale
Johns, M. W. (1991) · Sleep · doi:10.1093/sleep/14.6.540 · Cited by 17,364
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157
Measuring balance in the elderly: preliminary development of an instrument
Berg, K. (1989) · Physiotherapy Canada · doi:10.3138/ptc.41.6.304 · Cited by 2,742
A Rating Scale for Drug-Induced Akathisia
Barnes, T. R. E. (1989) · British Journal of Psychiatry · doi:10.1192/bjp.154.5.672 · Cited by 2,170
Unified Huntington's disease rating scale: Reliability and consistency
(1996) · Movement Disorders · doi:10.1002/mds.870110204 · Cited by 2,079
Global Rating of Change Scales: A Review of Strengths and Weaknesses and Considerations for Design
Kamper, S. J., Maher, C. G., & Mackay, G. (2009) · Journal of Manual & Manipulative Therapy · doi:10.1179/jmt.2009.17.3.163 · Cited by 1,458
Unified Huntington's disease rating scale: reliability and consistency
Kremer, H. P. H. (1996) · Radboud Repository (Radboud University) · Cited by 1,059
Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (2013) · PsycTESTS Dataset · doi:10.1037/t03589-000 · Cited by 946
Using Deuterium in Drug Discovery: Leaving the Label in the Drug
Gant, T. G. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm4007998 · Cited by 764
Assessing the clinical significance of change scores recorded on subjective outcome measures
Hurst, H., & Bolton, J. (2004) · Journal of Manipulative and Physiological Therapeutics · doi:10.1016/j.jmpt.2003.11.003 · Cited by 702
Schneider, L. S., Olin, J. T., Doody, R. S., Clark, C. M., Morris, J. C., Reisberg, B., Schmitt, F. A., Grundman, M., Thomas, R. G., & Ferris, S. H. (1997) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199700112-00004 · Cited by 647
Pharmacological uses and perspectives of heavy water and deuterated compounds
Kushner, D. J., Baker, A., & Dunstall, T. G. (1999) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-77-2-79 · Cited by 332
Tetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial
Savani, A. A., & Login, I. S. (2007) · Neurology · doi:10.1212/01.wnl.0000259143.52138.5c · Cited by 299
Armstrong, M. J., & Miyasaki, J. M. (2012) · Neurology · doi:10.1212/wnl.0b013e318263c443 · Cited by 180
Huntington's disease in Venezuela: Neurologic features and functional decline
Young, A. B., Shoulson, I., Penney, J. B., Starosta-Rubinstein, S., Gomez, F., Travers, H., Ramos-Arroyo, M. A., Snodgrass, S. R., Bonilla, E., Moreno, H., et al. (1986) · Neurology · doi:10.1212/wnl.36.2.244 · Cited by 179
Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders
Jankovic, J. J., & Clarence‐Smith, K. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.149 · Cited by 145
Self-citationNatural History of Huntington Disease
Dorsey, E. R. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.4408 · Cited by 124
Validation of a new scale for the evaluation of sialorrhea in patients with Parkinson's disease
Perez‐Lloret, S., Arce, G. P., Rossi, M., Nemet, M. L. C., Salsamendi, P., & Merello, M. (2006) · Movement Disorders · doi:10.1002/mds.21152 · Cited by 94
Advances in the Pharmacological Management of Huntingtonʼs Disease
Frank, S., & Jankovic, J. J. (2010) · Drugs · doi:10.2165/11534430-000000000-00000 · Cited by 71
Self-citationKinetic deuterium isotope effects in cytochrome P450 oxidation reactions
Guengerich, F. P. (2013) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3031 · Cited by 67
Chorea associated with Huntington's disease: To treat or not to treat?
Jankovic, J. J., & Roos, R. A. C. (2014) · Movement Disorders · doi:10.1002/mds.25996 · Cited by 67
Self-citationAnalysis of CYP2D6 genotype and response to tetrabenazine
Mehanna, R., Hunter, C., Davidson, A. L., Shahed, J. J., & Jankovic, J. J. (2012) · Movement Disorders · doi:10.1002/mds.25278 · Cited by 56
Self-citationRelationship of Mediterranean Diet and Caloric Intake to Phenoconversion in Huntington Disease
Marder, K. S., Gu, Y., Eberly, S. W., Tanner, C. M., Scarmeas, N., Oakes, D., & Shoulson, I. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.3487 · Cited by 55
Self-citationShen, V., Clarence‐Smith, K., Hunter, C., & Jankovic, J. J. (2013) · Tremor and Other Hyperkinetic Movements · doi:10.5334/tohm.129 · Cited by 36
Self-citationShen, V., Clarence‐Smith, K., Hunter, C., et al. (2013) · Europe PMC (PubMed Central) · doi:10.7916/d81z42c8 · Cited by 29
Self-citationHuntington's disease in Venezuela: Neurologic features and functional decline
Young, A. B., Shoulson, I., Penney, J., Starosta‐Rubinstein, S., Gomez, F., Travers, H., Ramos-Arroyo, M. A., Snodgrass, S., Bonilla, E., Moreno, H., et al. (2011) · Neurology · doi:10.1212/01.wnl.0000397841.29139.d7 · Cited by 14
Cited by
Huntington's disease: a clinical review
McColgan, P., & Tabrizi, S. J. (2018) · European Journal of Neurology · doi:10.1111/ene.13413 · Cited by 1,089
Deuterium in drug discovery: progress, opportunities and challenges
Di Martino, R. M. C., Maxwell, B. D., & Pirali, T. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00703-8 · Cited by 539
First deuterated drug approved
Schmidt, C. (2017) · Nature Biotechnology · doi:10.1038/nbt0617-493 · Cited by 466
Anderson, K. E., Stamler, D., Davis, M. D., Factor, S. A., Hauser, R. A., Isojärvi, J., Jarskog, L. F., Jimenez-Shahed, J., Kumar, R., McEvoy, J. P., et al. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30236-5 · Cited by 337
Self-citationRandomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study
Fernandez, H. H., Factor, S. A., Hauser, R. A., Jimenez-Shahed, J., Ondo, W. G., Jarskog, L. F., Meltzer, H. Y., Woods, S. W., Bega, D., LeDoux, M. S., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000003960 · Cited by 327
Self-citation
Metadata
- Authors
- Huntington Study Group, Frank, S., Testa, C. M., Stamler, D., Kayson, E., Davis, C., Edmondson, M. C., Kinel, S., Leavitt, B., Oakes, D., O’Neill, C., Vaughan, C., Goldstein, J., Herzog, M., Snively, V., Whaley, J., Wong, C., Suter, G., Jankovic, J., Jimenez-Shahed, J., Hunter, C., Claassen, D. O., Roman, O. C., Sung, V., Smith, J., Janicki, S., Clouse, R., Saint-Hilaire, M., Hohler, A., Turpin, D., James, R. C., Rodriguez, R., Rizer, K., Anderson, K. E., Heller, H., Carlson, A., Criswell, S., Racette, B. A., Revilla, F. J., Nucifora, F., Margolis, R. L., Ong, M., Mendis, T., Mendis, N., Singer, C., Quesada, M., Paulsen, J. S., Brashers-Krug, T., Miller, A., Kerr, J., Dubinsky, R. M., Gray, C., Factor, S. A., Sperin, E., Molho, E., Eglow, M., Evans, S., Kumar, R., Reeves, C., Samii, A., Chouinard, S., Beland, M., Scott, B. L., Hickey, P. T., Esmail, S., Fung, W. L. A., Gibbons, C., Qi, L., Colcher, A., Hackmyer, C., McGarry, A., Klos, K., Gudesblatt, M., Fafard, L., Graffitti, L., Schneider, D. P., Dhall, R., Wojcieszek, J. M., LaFaver, K., Duker, A., Neefus, E., Wilson-Perez, H., Shprecher, D., Wall, P., Blindauer, K. A., Wheeler, L., Boyd, J. T., Houston, E., Farbman, E. S., Agarwal, P., Eberly, S. W., Watts, A., Tariot, P. N., Feigin, A., Evans, S., Beck, C., Orme, C., Edicola, J., & Christopher, E.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2016-07-05
- Volume
- 316
- Issue
- 1
- Pages
- 40
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2475146005
- Cited by
- 403
- References
- 30
- FWCI
- 14.17
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.